Mineralys Therapeutics, Inc. (MLYS)

MLYS Biotech / Pharma

BiotechSign Signal Grade

D
Signal Grade
35.5/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Pdufa Date
55
Insider Buying
0
Dilution Risk
44
Clinical Activity
25
Short Interest
50
FDA PDUFA Target Date:2026-12-22 Source

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

1
Clinical Trial
(ClinicalTrials.gov aggregate)
1 Phase 3
Trial Phase Breakdown
0
PubMed Publications
1
Catalyst Record

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
14.2 months
Cash Runway Estimate
44/100
Dilution Score
40Warrant Risk
40Convertible Risk
52Offering Ability

Dilution score: 44/100 (MEDIUM), 14.2 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

12.93%
Float Shorted
5.2
Days to Cover
MODERATE
Squeeze Risk
-15.0%
SI Change
DECREASING
Trend
7,805,612
Shares Short

Short interest: 12.93% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Upcoming Catalysts

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Mineralys Therapeutics, Inc..

Full MLYS Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.